Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythaemia.

M A Bentley1, K M Taylor, S J Wright

  • 1mbentley@gil.com.au

The Medical Journal of Australia
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Essential thrombocythaemia (ET) is a blood cancer causing high platelet counts. Platelet-lowering therapy is recommended for counts over 1000 x 10(9)/L, while other treatments exist for younger patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collapse of Nuclear Collectivity along the N=Z Line.

Physical review letters·2026
Same author

Identification of Prompt Proton Emission in N=Z-1 ^{61}Ga: Isospin Symmetry at the Limit of Nuclear Binding.

Physical review letters·2025
Same author

Abrupt structural transition in exotic molybdenum isotopes unveils an isospin-symmetric island of inversion.

Nature communications·2025
Same author

US Army basic combat training alters the relationship between body mass index and per cent body fat.

BMJ military health·2021
Same author

Patient preferences for stratified medicine in psoriasis: a discrete choice experiment.

The British journal of dermatology·2021
Same author

Establishing the Maximum Collectivity in Highly Deformed N=Z Nuclei.

Physical review letters·2020

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Diagnosis involves excluding other myeloproliferative disorders and reactive thrombocytosis.
  • ET often presents as an incidental finding of thrombocytosis.

Purpose of the Study:

  • To outline diagnostic criteria for Essential thrombocythaemia.
  • To provide treatment recommendations based on platelet count and patient characteristics.
  • To discuss the risks and benefits of various therapeutic agents for ET.

Main Methods:

  • Diagnostic workup involves exclusion of other conditions.
  • Treatment decisions are guided by platelet count thresholds and patient age.

Related Experiment Videos

  • Review of existing therapeutic options including traditional and newer agents.

    • Main Results:

    • Platelet-lowering therapy is indicated for asymptomatic patients with platelet counts > 1000 x 10(9)/L.
    • Definitive recommendations are pending for asymptomatic patients with lower platelet counts.
    • Traditional therapies (alkylating agents, radioactive phosphorus, hydroxyurea) carry a risk of transformation to acute leukaemia.
    • Interferon alfa-2a and anagrelide are effective treatments, especially for younger patients.

    Conclusions:

    • Early intervention with platelet-lowering therapy is crucial for high-risk ET patients.
    • Careful consideration of treatment risks, including leukaemic transformation, is necessary.
    • Interferon alfa-2a and anagrelide represent valuable therapeutic options for specific ET patient groups.